Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression.

A 6-year-old male with vertebral-basilar artery thrombosis was recognized to have high-molecular-weight kininogen (HK) deficiency. The propositus had no HK procoagulant activity and antigen (< 1%). Using monoclonal antibodies (Mabs) to kininogen domain 3, the propositus, family members, and Fitzgerald plasma were determined to have detectable low-molecular-weight kininogen. Mabs to HK domains 5 and 6 do not detect HK antigen in the propositus' plasma. The propositus has a single base pair (bp) deletion in cDNA position 1492 of exon 10 affecting amino acid 480 of the mature protein and resulting in a frameshift and a premature stop codon at position 1597 (amino acid 532). Unexpectedly, Mabs to the heavy chain and domain 5 of HK detect a 92-kDa form of HK in Fitzgerald plasma, the first HK-deficient plasma. The 92-kDa Fitzgerald HK has amino acid residues through 502, corresponding to domains 1 through 5, but lacks epitopes of domain 6 (positions 543 to 595). Fitzgerald DNA has a normal exon 10, but a 17-bp mutation in intron 9. These combined results indicate that mutations in the kininogen gene may differentially affect biosynthesis, processing, and/or secretion of HK.

[1]  A. Schmaier,et al.  Identification of prolylcarboxypeptidase as the cell matrix‐associated prekallikrein activator , 2002, FEBS letters.

[2]  A. Schmaier,et al.  Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator* , 2002, The Journal of Biological Chemistry.

[3]  A. Schmaier The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. , 2002, The Journal of clinical investigation.

[4]  A. Schmaier,et al.  Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. , 2001, Blood.

[5]  A. Schmaier,et al.  Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. , 2001, American journal of physiology. Heart and circulatory physiology.

[6]  D. Shaw,et al.  Two‐chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5 , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  P. J. Anderson,et al.  Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease. , 2000, Genomics.

[8]  R. Colman,et al.  Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. , 2000, Blood.

[9]  T. Renné,et al.  Mapping of the Discontinuous H-kininogen Binding Site of Plasma Prekallikrein , 1999, The Journal of Biological Chemistry.

[10]  V. Nicaud,et al.  Venous Thromboembolic Disease and the Prothrombin, Methylene Tetrahydrofolate Reductase and Factor V Genes , 1999, Thrombosis and Haemostasis.

[11]  A. Schmaier,et al.  High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. , 1998, Blood.

[12]  R. Colman,et al.  High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. , 1997, Blood.

[13]  A. Schmaier,et al.  Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. , 1996, Circulation.

[14]  T. Renné,et al.  Mapping of the Discontinuous Kininogen Binding Site of Prekallikrein , 1996, The Journal of Biological Chemistry.

[15]  A. Schmaier,et al.  Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5 (*) , 1995, The Journal of Biological Chemistry.

[16]  R. Colman,et al.  Genetic basis of total kininogen deficiency in Williams' trait. , 1993, The Journal of biological chemistry.

[17]  M. Haasemann,et al.  Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties. , 1993, The Journal of biological chemistry.

[18]  A. Schmaier,et al.  High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. , 1992, Blood.

[19]  A. Schmaier,et al.  Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. , 1992, The Journal of biological chemistry.

[20]  A. Schmaier,et al.  Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. , 1991, The Journal of biological chemistry.

[21]  J. Kellermann,et al.  Mapping of the prekallikrein-binding site of human H-kininogen by ligand screening of lambda gt11 expression libraries. Mimicking of the predicted binding site by anti-idiotypic antibodies. , 1990, The Journal of biological chemistry.

[22]  A. Kakizuka,et al.  A set of U1 snRNA-complementary sequences involved in governing alternative RNA splicing of the kininogen genes. , 1990, The Journal of biological chemistry.

[23]  T. Tsuda,et al.  Molecular genetic survey of five Japanese families with high-molecular-weight kininogen deficiency. , 1990, Blood.

[24]  R. Schein,et al.  Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. , 1988, The Journal of laboratory and clinical medicine.

[25]  N. Kitamura,et al.  Localization of DNA sequences governing alternative mRNA production of rat kininogen genes. , 1988, The Journal of biological chemistry.

[26]  K. Fujikawa,et al.  Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. , 1987, The Journal of biological chemistry.

[27]  R. Colman,et al.  Evaluation of a microassay for human plasma prekallikrein. , 1987, The Journal of laboratory and clinical medicine.

[28]  A. Schmaier,et al.  Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. , 1987, The Journal of biological chemistry.

[29]  A. Barrett,et al.  Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. , 1986, The Biochemical journal.

[30]  A. Schmaier,et al.  High-molecular weight kininogen. A secreted platelet protein. , 1983, The Journal of clinical investigation.

[31]  O. Carretero,et al.  Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. , 1982, The Journal of laboratory and clinical medicine.

[32]  R. Colman,et al.  Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. , 1980, The Journal of clinical investigation.

[33]  E. G. Erdös,et al.  Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. , 1978, The Journal of biological chemistry.

[34]  R. Colman,et al.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. , 1975, The Journal of clinical investigation.

[35]  R. Waldmann,et al.  FITZGERALD FACTOR: A HITHERTO UNRECOGNISED COAGULATION FACTOR , 1975, The Lancet.